Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
jbtherapeutics.com

See what CB Insights has to offer

Stage

Merger | Merged

Total Raised

$1.5M

About JB Therapeutics

JB Therapeutics is a clinical stage biopharmaceutical company developing a class of analgesic agents. The company's lead compound, JBT-101, is a CB1 and CB2 agonist with demonstrated efficacy in several animal models of pain and inflammation. It has also completed a Phase II clinical study in chronic refractory neuropathic pain. JBT-101 is being developed as a potential disease modifying treatment for osteoarthritis. JBT-101 also represents a platform for combination with other anti-inflammatory and analgesic agents as well as various drug delivery strategies including ointment and gels, topical patches, and timed release formulations.

JB Therapeutics Headquarter Location

508 Dudley Road Suite 100

Newton, Massachusetts, 02459,

United States

617-413-3020

Latest JB Therapeutics News

citybizlist : Boston : Corbus Raises $6.3 Million for Merger with JB Therapeutics

Nov 10, 2015

Corbus Raises $6.3 Million for Merger with JB Therapeutics 4/27/14 By citybizlist Staff Corbus Pharmaceuticals Holdings Inc. has raised $6.3 million, or about 48% of a $13 million equity offering, from 45 investors, according to an SEC filing. The offering is being made in connection with the merger of Corbus? wholly owned subsidiary with JB Therapeutics Inc. The stockholders of JB received 9 million Corbus shares and 917,612 warrants exercisable at $1 per share. Corbus is a clinical stage biopharmaceutical company developing drugs to treat life-threatening inflammatory-fibrotic diseases. Its leading candidate drug Resunab treats chronic inflammatory diseases leading to chronic fibrosis. The drug has completed its pre-clinical development and a Phase 1 safety study, and is scheduled to begin its first-in-patient Phase 2 clinical studies in 2014. The Cambridge-based company was co-founded in 2009 by Mark A. Tepper, Ph.D. Dr. Tepper is now the president and chief scientific officer. The company is led by CEO Yuval Cohen, PhD. Prior to joining Corbus, he was the president and co-founder of Celsus Therapeutics (Nasdaq CLTX) from 2005 to June 2013. Corbus? placement agent, New York-based Aegis Capital Corp., received $1.3 million in sales commissions. Stories you Need to Know Stories you Need to Know It's on us. Share your news here. Commercial Real Estate Posted on 11/10/15

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing JB Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

JB Therapeutics is included in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

N

Neuroscience

2,144 items

Companies developing products that monitor, analyze, protect, or otherwise influence the structure/function of the nervous system.

JB Therapeutics Patents

JB Therapeutics has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/23/2009

1/28/2014

Analgesics, Phenols, Cannabinoids, Chronic pain syndromes, Gynaecology

Grant

Application Date

11/23/2009

Grant Date

1/28/2014

Title

Related Topics

Analgesics, Phenols, Cannabinoids, Chronic pain syndromes, Gynaecology

Status

Grant

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.